journal article·2023-06-28

Silica Nanoparticles Promote the Megakaryocyte Maturation and Differentiation: Potential Implications for Hematological Homeostasis

Xiaoting Jin, Ze Zhang, Ge Guan, Qunfang Zhou, Yuxin Zheng, Guibin Jiang

ACS Applied Materials & Interfaces· Volume 15· Issue 25
Publisher page

Abstract

Silica nanoparticles (SiO 2 NPs) have been widely applied in diverse areas, thus causing the extensive release through multiple routes. Their toxicological effects, especially for the disturbance in hematological homeostasis, have raised public concern. Considering the detrimental role of excessive platelets in many cardiovascular diseases, the regulation of platelet formation offers a unique aspect for studying the blood compatibility of nanomaterials. In this study, the effects of SiO 2 NPs with four sizes (80, 120, 200, and 400 nm) were investigated on the maturation and differentiation of the megakaryocytes into platelets. The results showed that SiO 2 NPs promoted megakaryocyte development as manifested by the occurrence of irregular cell morphology, enlargement of cell size, increases in DNA content and DNA ploidy, and formation of spore-like protrusions. The expression of megakaryocyte-specific antigen (CD41a) was up-regulated, due to SiO 2 NP treatments. The correlation analysis of SiO 2 NP size with the above test bioindicators showed that the smaller the SiO 2 NPs were, the stronger effects they induced. Moreover, exposure to SiO 2 NPs induced the up-regulation of both GATA-1 and FLI-1, while the transcriptional expressions of aNF-E2 and fNF-E2 remained unchanged. The significant positive correlation of GATA-1 and FLI-1 with megakaryocytic maturation and differentiation suggested their crucial roles in the SiO 2 NP-promoted effect. The finding herein provided new insight into the potential health risk of SiO 2 NPs by perturbing the platelet-involved hematological homeostasis.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Platelet Disorders and Treatments · Acute Myeloid Leukemia Research · Chemotherapy-induced organ toxicity mitigation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Environmental Chemistry and Ecotoxicology, Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing 100085, P. R. China

School of Public Health, Qingdao University, Qingdao, Shandong 266071, P. R. China

College of Resources and Environment, University of Chinese Academy of Sciences, Beijing 100049, P. R. China

Institute of Environment and Health, Jianghan University, Wuhan 430056, P. R. China

Funding

National Natural Science Foundation of China

References (46)

Show source-provided references
1. 10.1016/j.jhazmat.2015.01.06310.1016/j.jhazmat.2015.01.063 ↗
2. WHO · 2017
3. 10.1016/S2213-2600(19)30078-510.1016/S2213-2600(19)30078-5 ↗
4. 10.1186/s12951-020-00634-110.1186/s12951-020-00634-1 ↗
5. 10.1016/S0140-6736(12)60235-910.1016/S0140-6736(12)60235-9 ↗
6. 10.1021/acsnano.9b0301910.1021/acsnano.9b03019 ↗
7. 10.1016/j.jid.2018.08.02410.1016/j.jid.2018.08.024 ↗
8. 10.1016/j.pharmthera.2022.10812010.1016/j.pharmthera.2022.108120 ↗
9. 10.2147/IJN.S2829310.2147/IJN.S28293 ↗
10. 10.1016/j.biopha.2022.11276810.1016/j.biopha.2022.112768 ↗
11. 10.2147/IJN.S5281810.2147/IJN.S52818 ↗
12. 10.1164/rccm.200508-1243PP10.1164/rccm.200508-1243PP ↗
13. 10.1007/s10555-017-9677-x10.1007/s10555-017-9677-x ↗
14. 10.1038/nrdp.2015.610.1038/nrdp.2015.6 ↗
15. 10.1080/00015385.2017.128156010.1080/00015385.2017.1281560 ↗
16. 10.1083/jcb.20130405410.1083/jcb.201304054 ↗
17. 10.1186/s12989-021-00411-410.1186/s12989-021-00411-4 ↗
18. 10.1016/j.ejpb.2009.03.00710.1016/j.ejpb.2009.03.007 ↗
19. 10.1289/ehp.733910.1289/ehp.7339 ↗
20. 10.1002/smll.20080046110.1002/smll.200800461 ↗
21. 10.1007/s12012-013-9198-y10.1007/s12012-013-9198-y ↗
22. 10.1088/1748-605X/12/1/01500110.1088/1748-605X/12/1/015001 ↗
23. 10.1038/s41598-021-99815-710.1038/s41598-021-99815-7 ↗
24. 10.1016/j.scitotenv.2021.15236810.1016/j.scitotenv.2021.152368 ↗
25. 10.1016/0021-9797(68)90272-510.1016/0021-9797(68)90272-5 ↗
26. 10.1093/toxsci/kfac07910.1093/toxsci/kfac079 ↗
27. 10.1016/j.scitotenv.2018.02.04710.1016/j.scitotenv.2018.02.047 ↗
28. 10.3390/ijms1812254910.3390/ijms18122549 ↗
29. 10.1039/D0TB00012D10.1039/D0TB00012D ↗
30. 10.1021/nn800511k10.1021/nn800511k ↗
31. 10.1016/j.biomaterials.2011.07.03610.1016/j.biomaterials.2011.07.036 ↗
32. 10.1111/bcpt.1296310.1111/bcpt.12963 ↗
33. 10.1371/journal.pone.006134610.1371/journal.pone.0061346 ↗
34. 10.2147/IJN.S20274110.2147/IJN.S202741 ↗
35. 10.1016/j.msec.2015.09.03210.1016/j.msec.2015.09.032 ↗
36. 10.1002/cam4.75910.1002/cam4.759 ↗
37. Nemmar A. · Int. J. Physiol., Pathophysiol. Pharmacol. · 2015 · 7 · 27
38. 10.1007/s00018-006-6190-810.1007/s00018-006-6190-8 ↗
39. 10.1111/j.1538-7836.2011.04396.x10.1111/j.1538-7836.2011.04396.x ↗
40. 10.1182/blood-2005-02-055110.1182/blood-2005-02-0551 ↗
41. 10.1182/blood-2011-04-28598110.1182/blood-2011-04-285981 ↗
42. 10.1084/jem.2019120610.1084/jem.20191206 ↗
43. 10.1002/tox.2313410.1002/tox.23134 ↗
44. 10.1021/ja211307u10.1021/ja211307u ↗
45. 10.1039/C6BM00921B10.1039/C6BM00921B ↗
46. 10.1111/j.1538-7836.2007.02472.x10.1111/j.1538-7836.2007.02472.x ↗